2019 Update of DiaCarta Inc, Product Pipeline Analysis – Serving Germany, Egypt, Iran, Turkey, Iraq & Costa Rica – ResearchAndMarkets.com

DUBLIN–(BUSINESS WIRE)–The “DiaCarta Inc – Product Pipeline Analysis, 2019 Update” company profile has been added to ResearchAndMarkets.com’s offering.

Summary

DiaCarta Inc (DiaCarta) is a developer of molecular diagnostics products for cancer and infectious diseases. The company offers genomic testing for biomarkers and also provides clinical sample testing services in their CLIA-certified lab. It offers products such as gene mutation detection kits, colon cancer tests, fusion gene detection tests, adapter dimer removal, DNA sample card, CRISPR gene editing, PCR ready lysis buffers and genotyping tests, among others. DiaCarta provides services including CLIA lab services; NGS target sequencing, next generation sequencing, companion diagnostics and CAR-T immunotherapy. The company markets its products through a channel of network distributors. DiaCarta is headquartered in Richmond, California, The US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

• The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
• The report analyzes all pipeline products in development for the company DiaCarta Inc
• The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
• The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
• The report provides detailed description of products in development, technical specification and functions
• The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design , trial status and phase, estimated start and end date.

Reasons to Buy:

• Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
• Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
• To formulate effective Research & Development strategies
• Develop market-entry and market expansion strategies
• Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
• Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
• Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
• Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
• Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio

Key Topics Covered:

• DiaCarta Inc Company Overview
• DiaCarta Inc Company Snapshot
• DiaCarta Inc Pipeline Products and Ongoing Clinical Trials Overview
• DiaCarta Inc – Pipeline Analysis Overview
• DiaCarta Inc – Key Facts
• DiaCarta Inc – Major Products and Services
• DiaCarta Inc Pipeline Products by Development Stage
• DiaCarta Inc Pipeline Products Overview
• ColoScape Colorectal Cancer Mutation Detection Test
• ColoScape Colorectal Cancer Mutation Detection Test Product Overview
• Next Generation HPV Genotyping E6/E7 mRNA Test
• Next Generation HPV Genotyping E6/E7 mRNA Test Product Overview
• RadTox QuantiDNA
• RadTox QuantiDNA Product Overview
• TB Drug Resistance Mutation Test
• TB Drug Resistance Mutation Test Product Overview
• DiaCarta Inc – Key Competitors
• DiaCarta Inc – Key Employees
• DiaCarta Inc – Locations And Subsidiaries
• Head Office
• Other Locations & Subsidiaries
• Recent Developments
• DiaCarta Inc, Recent Developments
• Oct 15, 2018: DiaCarta Awarded $2 Million NCI Contract to Pursue Regulatory Approval of Innovative Cancer Radiation Response Blood Test
• Jul 31, 2018: DiaCarta Named to MedTech Outlook’s Top 10 In-Vitro Diagnostic Technology Solution Providers 2018
• Jul 02, 2018: DiaCarta Appoints Arrow Diagnostics as Exclusive Distributor for ColoScape in Italy
• Feb 20, 2017: DiaCarta Receives CE-IVD for its Non-Invasive Colorectal Cancer Test – ColoScape Real-Time PCR Kit
• Oct 26, 2016: DiaCarta Receives NCI Contract for a Circulating Free DNA (cfDNA) Test to Monitor Radiation Response in Cancer Patients
• Sep 26, 2016: DiaCarta Introduces QFusion Single-Tube qPCR Assay for ALK Fusion Gene Detection
• Appendix
• Methodology
• About the Author
• Contact Us
• Disclaimer

Companies Mentioned

• Iovance Biotherapeutics Inc
• EnCor Biotechnology Inc
• BBC Entrepreneurial Training & Consulting LLC

For more information about this company profile visit https://www.researchandmarkets.com/r/j87fpk

Contacts

ResearchAndMarkets.com

Laura Wood, Senior Press Manager

[email protected]
For E.S.T Office Hours Call 1-917-300-0470

For U.S./CAN Toll Free Call 1-800-526-8630

For GMT Office Hours Call +353-1-416-8900